NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

CG Oncology, Inc. (CGON) Stock Analysis

CG Oncology, Inc. (CGON) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CGON

$74.67

+$0.34 (+0.46%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CGON with… →

CGON Key Statistics

As of Sep 4, 2026
Trading
Open
$73.02
Previous Close
$74.33
Day's Range
72.87–74.88
52-Week Range
32.08–80.97
Volume
282.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.24
Valuation
Market Cap
$6.62B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1062.75
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.70
Financials (FY)
Revenue (FY)
$4.04M+254.70%
Net Income (FY)
−$161.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
88.64M
1-Year Return
+141.34%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
965.91K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CGON Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+79.84%
2025+44.77%
2024−22.84%

As of September 4, 2026.

CGON Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.04M−$161.00M−3985.0%
2024$1.14M−$88.04M−7729.5%
2023$204.00K−$48.61M−23827.0%
2022$191.00K−$35.44M−18556.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.04M−$607.00K−$190.77M−$161.00M−3985.0%
2024$1.14M$1.14M−$114.67M−$88.04M−7729.5%
2023$204.00K$204.00K−$55.45M−$48.61M−23827.0%
2022$191.00K—−$35.25M−$35.44M−18556.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CGON Valuation vs Biotechnology Median

Median of 656 stocks
MetricCGONBiotechnology medianvs median
P/S ratio1062.7515.2669.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values CG Oncology, Inc. (CGON) at $6.62B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 142.

Over the past 52 weeks the price has ranged from $32.08 to $80.97. CGON last closed at $74.67 on September 4, 2026. That is +$0.34 (+0.46%) against the previous close. The latest close sits 132.76% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.04M. Against the prior fiscal year total of $1.14M, that is a change of +254.70%. The same year closed with a net loss of $161.00M. The reported profit margin is 0%. Trailing earnings per share are −2.7.

Across the 4 fiscal years on file, revenue moves from $191.00K in 2022 to $4.04M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1,062.75 times revenue. On price-to-sales that is 69.6 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +141.34%. The stored price history starts on January 25, 2024, and the total return since then is +100.89%. Beta against the wider market is reported at 0.24. Annualized volatility over the trailing 2 years is 61.05%.

Growth & Income

The record shows no dividend for CGON.

The strongest complete calendar year on file is 2025 at +44.77%; the weakest is 2024 at −22.84%. 2026 is still running; the price is +79.84% year to date.

Peer Comparison

CG Oncology, Inc. (CGON) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CG Oncology, Inc. CGON $6.62B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. CG Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CG Oncology, Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Visit website →